Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Denufosol tetrasodium: Completed Phase III enrollment

ISPH completed enrollment of about 350 patients in the double-blind U.S. Phase

Read the full 123 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE